Status: Recruiting
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, and after the implementation of a universal immunization program. The impact of the program on RSV-related health outcomes will also be determined.
Participants needed: 160,000
Trial details
Age: Up to 4Biological sex: AllType: ObservationalSponsor: Instituto Sistemas Complejos de IngenieríaUpdated: Jul 22, 2024Locations: 1
Eligibility criteria
Subjects born between October 1st, 2023, to September 31st, 2024. [+2]
No specific criteria has been reported